Cyclophilin A differentially activates monocytes and endothelial cells. Role of purity, activity, and endotoxin contamination in commercial preparations

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 564-571

  Payeli, Sravan K ^a   Schiene Fischer, Cordelia ^c   Steffel, Jan ^a,b   Camici, Giovanni G ^a   Rozenberg, Izabela ^a   Lüscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

Author keywords

Cyclophilin A; Endothelial cells; Lipopolysaccharide; Monocytes; Tissue factor

Indexed keywords

CHEMOATTRACTANT; CYCLOPHILIN A; CYCLOSPORIN A; CYTOPLASM PROTEIN; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEPTIDYLPROLYL ISOMERASE; RECOMBINANT CYCLOPHILIN A; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL LINE; CELL MIGRATION; CHEMOTAXIS; CONTAMINATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SPECTRUM ANALYSIS; PURIFICATION; SPECTROSCOPY;

AORTA; CELLS, CULTURED; CHEMOTACTIC FACTORS; CYCLOPHILIN A; DRUG CONTAMINATION; ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 40949095190     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.08.025     Document Type: Article

References (25)

1. Wang P., and Heitman J. The cyclophilins. Genome Biol 6 7 (2005) 226
2. Ryffel B., Woerly G., Greiner B., et al. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology 72 3 (1991) 399-404
3. Fischer G., Wittmann-Liebold B., Lang K., Kiefhaber T., and Schmid F.X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337 6206 (1989) 476-478
4. Piotukh K., Gu W., Kofler M., et al. Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J Biol Chem 280 25 (2005) 23668-23674
5. Fruman D.A., Klee C.B., Bierer B.E., and Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 89 9 (1992) 3686-3690
6. Clardy J. The chemistry of signal transduction. Proc Natl Acad Sci USA 92 1 (1995) 56-61
7. Sherry B., Yarlett N., Strupp A., and Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA 89 8 (1992) 3511-3515
8. Kim S.H., Lessner S.M., Sakurai Y., and Galis Z.S. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 164 5 (2004) 1567-1574
9. Suzuki J., Jin Z.G., Meoli D.F., Matoba T., and Berk B.C. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 98 6 (2006) 811-817
10. Jin Z.G., Lungu A.O., Xie L., et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 24 7 (2004) 1186-1191
11. Camici G.G., Steffel J., Akhmedov A., et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 114 14 (2006) 1512-1521
12. Steffel J., Latini R.A., Akhmedov A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 13 (2005) 2002-2011
13. Steffel J., Akhmedov A., Greutert H., Luscher T.F., and Tanner F.C. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 112 3 (2005) 341-349
14. Steffel J., Hermann M., Greutert H., et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111 13 (2005) 1685-1689
15. Weiss S., Frischknecht K., Greutert H., et al. Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway. J Vasc Res 44 2 (2007) 149-156
16. Gao B., and Tsan M.F. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 278 1 (2003) 174-179
17. Billich A., Winkler G., Aschauer H., Rot A., and Peichl P. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med 185 5 (1997) 975-980
18. Libby P. Inflammation in atherosclerosis. Nature 420 6917 (2002) 868-874
19. Pathak S.K., Basu S., Bhattacharyya A., et al. TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages. J Immunol 177 11 (2006) 7950-7958
20. Drew A.F., and Tipping P.G. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 116 2 (1995) 181-189
21. Diederich D., Yang Z., and Luscher T.F. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 2 8 (1992) 1291-1297
22. Redondo-Horcajo M., and Lamas S. Oxidative and nitrosative stress in kidney disease: a case for cyclosporine A. J Nephrol 18 4 (2005) 453-457
23. Gamba A., Mamprin F., Fiocchi R., et al. The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clin Cardiol 20 9 (1997) 767-772
24. Gamba A., Mammana C., Fiocchi R., Iamele L., and Mamprin F. Cyclosporine and graft coronary artery disease after heart transplantation. Compr Ther 26 2 (2000) 121-126
25. Tanaka M., Mokhtari G.K., Balsam L.B., et al. Cyclosporine mitigates graft coronary artery disease in murine cardiac allografts: description and validation of a novel fully allogeneic model. J Heart Lung Transplant 24 4 (2005) 446-453